Esperion Therapeutics (NASDAQ:ESPR) Upgraded by StockNews.com to “Buy”

StockNews.com upgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a hold rating to a buy rating in a research report report published on Tuesday morning.

ESPR has been the topic of several other research reports. HC Wainwright restated a buy rating and set a $16.00 target price on shares of Esperion Therapeutics in a report on Wednesday, October 2nd. Bank of America cut Esperion Therapeutics from a neutral rating to an underperform rating and reduced their price objective for the stock from $2.90 to $2.50 in a research note on Thursday, June 20th. Finally, Needham & Company LLC lowered their target price on Esperion Therapeutics from $8.00 to $6.00 and set a buy rating for the company in a research note on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of Hold and a consensus target price of $8.17.

Esperion Therapeutics Price Performance

Shares of NASDAQ:ESPR opened at $2.13 on Tuesday. The business has a 50-day moving average of $1.82 and a two-hundred day moving average of $2.17. The firm has a market capitalization of $403.55 million, a PE ratio of -2.15 and a beta of 1.00. Esperion Therapeutics has a 12 month low of $0.71 and a 12 month high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. The business had revenue of $73.83 million for the quarter, compared to analyst estimates of $51.90 million. As a group, research analysts anticipate that Esperion Therapeutics will post -0.04 earnings per share for the current year.

Institutional Investors Weigh In On Esperion Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Capital Advisors Wealth Management LLC grew its stake in shares of Esperion Therapeutics by 22.9% during the second quarter. Capital Advisors Wealth Management LLC now owns 26,800 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 5,000 shares in the last quarter. Boomfish Wealth Group LLC boosted its holdings in Esperion Therapeutics by 17.1% in the third quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock valued at $58,000 after purchasing an additional 5,102 shares during the last quarter. Summit Financial LLC grew its stake in Esperion Therapeutics by 26.4% during the 2nd quarter. Summit Financial LLC now owns 32,687 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 6,823 shares in the last quarter. National Bank of Canada FI grew its stake in Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 10,225 shares in the last quarter. Finally, SG Americas Securities LLC increased its holdings in Esperion Therapeutics by 45.3% during the 2nd quarter. SG Americas Securities LLC now owns 37,414 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 11,658 shares during the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.